Skip to main content
TipRanks
Go Ultimate75% OFF

TerrAscend Corp (TSNDF) Q3 2026 Earnings Report

179 Followers

TSNDF Q3 2026 EPS Results

Actual EPS
-$0.02
Consensus EPS
-$0.02
Beat/Miss
Met expectations
One Year Ago EPS
-$0.04

TSNDF Q3 2026 Revenue Results

Actual Revenue
$66.91M
Expected Revenue
$66.82M
Beat/Miss
Beat by +$93.58K
YoY Revenue Growth
+6.51%

Earnings Announcement Details

Quarter
Q3 2026
Date
11/05/2026
Time
After Close
Conference Call
Thursday, November 5, 2026
TSNDF Upcoming Earnings

TerrAscend Corp's next earnings date is estimated for March 18, 2027, based on past reporting schedules.

Q3 2026 Earnings Call Audio

No earnings call audio is available for this earnings event.

Q3 2026 Earnings Slide Deck

No slide deck is available for this earnings event.

Q3 2026 Earnings Call Summary

Q3 2026
Earnings Call Date:Nov 05, 2026|% Change Since:-18.32%|
Earnings Call Sentiment|Positive

The call was strongly positive overall. TerrAscend reported year-over-year growth in revenue, gross margin and adjusted EBITDA, sustained consecutive-quarter records of positive operating and free cash flow, strong performance in Pennsylvania and Maryland, progress in New Jersey and Ohio, and substantial liquidity for acquisitions and investment. The main challenges were New Jersey competition and price compression, higher G&A expenses, a modest decline in adjusted EBITDA margin, ongoing net losses, and uncertainty around broader regulatory reform. Highlights significantly outweighed lowlights.

Company Guidance

Management expects mid-single-digit year-over-year revenue growth in Q4 2026 and consistent strong gross margin performance; in New Jersey, it is conservatively planning for about 20% more greenhouse yield from the Boonton cultivation facility, while Pennsylvania has additional capacity available and no CapEx expansion is currently needed to flex up with organic demand, adult use potential and the hemp loop closing in December.

  • Year-over-Year Revenue and Profitability GrowthThird-quarter revenue totaled $68.2 million, up approximately 5% from $65.1 million in the third quarter of 2025. Gross margin increased to 52.3% from 52.1%, and adjusted EBITDA rose to $17.5 million from $17 million.
  • Consistent Positive Cash Flow GenerationThe company generated $8.8 million of net cash from operations and $6.1 million of free cash flow during the quarter. This marked the 17th consecutive quarter of positive operating cash flow and the 13th consecutive quarter of positive free cash flow, representing a 17.7% operating cash flow yield and a 14% free cash flow yield.
  • Strong Liquidity and Financial FlexibilityTerrAscend ended the quarter with $42.5 million in cash. Management said continued free cash flow generation, the strong balance sheet and access to capital through the term loan facility provide flexibility for additional opportunities. No material debt is maturing until 2028.
  • Aunt Mary's Acquisition Adds New Jersey DispensaryThe company closed its Aunt Mary's transaction in September, adding its fifth dispensary in New Jersey. The dispensary generates over $10 million in annualized revenue and is immediately accretive on an EBITDA and free cash flow basis, although it contributed only marginally to third-quarter revenue because it closed late in the quarter.
  • Pennsylvania Delivered Strong Growth and Margin ExpansionPennsylvania revenue increased 16.8% year-over-year, driven by 12% same-store sales growth and a 31% increase in wholesale revenue. Gross margins expanded by 800 basis points, the business recorded its fourth consecutive quarter of sequential revenue growth, and Pennsylvania was the company's fastest-growing core market during the quarter.
  • Pennsylvania Retail and Brand PerformanceFive of the company's six Apothecarium locations ranked among the top 15 stores in Pennsylvania. TerrAscend gained market share across product categories, introduced 100-milligram medical troches that quickly became one of its best-selling SKUs, achieved 21% share in sublingual products, and had five of the top 15 sublingual SKUs through Ilera-branded tinctures.
  • Pennsylvania Cultivation Capacity Supports Future DemandThe Pennsylvania cultivation and manufacturing facility was operating at its highest utilization rate in years, with finished flower output increasing 68% year-over-year. Management said additional capacity remains available, the facility is almost at 50% capacity, and the company can increase output without additional capital expenditures.
  • Maryland Continued to Grow with Strong MarginsMaryland revenue grew both year-over-year and sequentially while gross margins remained roughly flat. The operation is running at an annualized revenue level of approximately $75 million, with gross margins in the high 50s.
  • Maryland Market Share and Product MomentumTerrAscend gained market share across flower, pre-rolls and vapes in Maryland. New product launches supported growth in Valhalla over the last two quarters, while new Kind Tree and Tyson 2.0 edibles generated nearly an additional point of market share during the quarter.
  • New Jersey Brand Position and Capacity ExpansionDespite increased retail competition and price compression, New Jersey revenue increased slightly year-over-year, and TerrAscend gained sales and market share across key product categories. The company completed a major phase of its Boonton cultivation expansion on budget and is conservatively planning for about 20% more greenhouse yield.
  • Strong New Jersey Product RankingsTerrAscend ranked third in New Jersey flower with an 8.3% share. Its Legend vape cartridge remained the number one vape cartridge brand with a 12.1% share among 215 brands.
  • Ohio Sales Growth Following Hemp RestrictionsOhio sales grew double digits percentage-wise year-over-year as the company captured consumers returning to the regulated market following the state's ban on intoxicating hemp products.
  • Disciplined Acquisition and Capital Allocation StrategyManagement said it is focused on disciplined, accretive acquisitions in existing markets and select new markets, including New Jersey, Pennsylvania, Ohio, Florida and Missouri. The company is balancing M&A with growth investments and capital expenditures and said it is evaluating several opportunities.
  • Share Repurchase Program ContinuedIn August, the company renewed and replenished authorization to repurchase up to the lesser of 10 million common shares or $10 million of common shares for the period from August 24, 2026 through August 23, 2027. During the quarter's 35 trading days in the open trading window, TerrAscend repurchased 1.013 million shares.
  • Regulatory Reform Could Improve ProfitabilityManagement described the rescheduling of state-licensed medical cannabis to Schedule III earlier in the year as a monumental industry inflection point. The company said the elimination of the 280E tax burden on medical cannabis will materially improve profitability and cash flow generation, strengthen the balance sheet and lower its cost of capital over time. Potential retroactive tax relief was also identified as a significant upside opportunity.
  • Progress Toward Exchange Listing and Hemp-Market OpportunityTerrAscend remains in active dialogue with major U.S. exchanges and continues preparing for a potential listing. Management also said enforcement against unregulated hemp products is building ahead of the intoxicating hemp ban scheduled for December 11 and expects to serve consumers returning to the regulated market.
  • Q4 Revenue and Margin OutlookManagement expects mid-single-digit year-over-year revenue growth in the fourth quarter of 2026 and expects consistent strong gross margin performance.

TSNDF Earnings History

TSNDF earnings history
Report DateFiscal QuarterForecast / EPSLast Year's EPSEPS YoY ChangePress Release
Mar 18, 20272026 (Q4)0.01-0.01――
Nov 05, 20262026 (Q3)-0.02-0.02-0.0450.00% (+0.02)
Aug 06, 20262026 (Q2)-0.01-0.03-0.030.00% (+0.00)
May 07, 20262026 (Q1)-0.01-0.03-0.0540.00% (+0.02)
Mar 12, 20262025 (Q4)-0.010.01-0.11109.09% (+0.12)
Nov 06, 20252025 (Q3)-0.02-0.04-0.0850.00% (+0.04)
Aug 07, 20252025 (Q2)-0.03-0.03-0.030.00% (+0.00)
May 08, 20252025 (Q1)-0.03-0.05-0.0616.67% (+0.01)
Mar 06, 20252024 (Q4)-0.03-0.11-0.1838.89% (+0.07)
Nov 06, 20242024 (Q3)-0.03-0.08-0.02-247.83% (-0.06)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat Missed